[Advance of study on JAK2 V617F in myeloproliferative disorders -- review].
The key molecular events in the pathogenesis of myeloproliferative disorders (MPD) have been poorly defined to date, except the case of chronic myeloid leukaemia with the associated rearranged gene bcr/abl. In recent years, a number of different studies described the detection of JAK2 V617F mutation in haematopoietic cells from polycythemia vera patients and other MPDs, which indicates that it plays an important role in the pathogenesis of MPDs. In this review, the JAK2 V617F point mutation and its detection methods, its clinical correlations with MPDs and other malignant hepatopathies were summarized.
Xu
Yuan-Yuan
YY
Department of Hematology, Kunming Medical College, Kunming 650021, China.
Li
Hui-Min
HM
D006801:Humans; D053614:Janus Kinase 2 / Q000235:genetics*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000235:genetics*; D009196:Myeloproliferative Disorders / Q000235:genetics*
C507924:JAK2 protein, human; D053614:Janus Kinase 2